RxDoctor Payments DataLook up a doctor →

Danka Michaels, MD

Internal Medicine · Las Vegas, NVNPI 1730151044

Payments from drug & device makers

$11,899in general payments, 2019–2025

Across 491 payments — averaging $24.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Novo Nordisk$933
  • AstraZeneca$885
  • Astellas Pharma US Inc$716
  • GSK$691
  • Amgen$665
  • plus $4K from 47 others

What the payments were for

  • Speaking & faculty fees$2,92825%
  • Food & beverage$8,46471%
  • Education$5074%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,899 in reported general payments places this provider in the 95th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$442,524
Medicare patients
775
Services billed
4,458

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide204$250,929
JardianceEmpagliflozin100$125,837
EliquisApixaban81$103,667
FarxigaDapagliflozin Propanediol74$75,374
MounjaroTirzepatide55$61,023
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$34,801
TrulicityDulaglutide20$29,551
XareltoRivaroxaban20$24,433
MyrbetriqMirabegron21$23,291
ProliaDenosumab12$21,350
JanuviaSitagliptin Phosphate14$21,148
JanumetSitagliptin Phos/Metformin Hcl12$18,227
Tresiba Flextouch U-200Insulin Degludec18$15,491
Estradiol72$9,801
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog23$8,526

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$933$250,929204 claims
Boehringer IngelheimJardiance$245$125,837100 claims
PfizerEliquis$298$103,66781 claims
Lilly USA, LLCMounjaro, Trulicity$174$90,57475 claims
AstraZenecaFarxiga$885$75,37474 claims
MerckJanuvia, Janumet, Belsomra$30$47,30838 claims
GSKTrelegy Ellipta$691$34,80142 claims
Johnson & JohnsonXarelto$46$24,43320 claims
Astellas Pharma US IncMyrbetriq$716$23,29121 claims
AmgenProlia$665$21,35012 claims
AbbVieSynthroid$3,959$5,29287 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →